Some immune checkpoint inhibitors (ICIs) may cause serious cardiotoxicities, including myocarditis, according to new data published in Circulation.
The study's authored noted that has been difficult to define the clinical features of ICI-related myocarditis (ICI-myocarditis). Could their findings be a step forward?
The group established an international registry with data from 49 different institutions in 11 countries, focusing on 125 reported cases of ICI-myocarditis that included electrocardiogram (ECG) findings. The ICIs involved in these cases were primarily ipilimumab, nivolumab and pembrolizumab.
Two cardiologists analyzed each ECG while blinded to the individual case and outcomes, confirming that ICI-myocarditis "is highly arrhythmogenic." Patients were diagnosed with a wide range of ECG abnormalities, including conduction blocks, decreased voltage, and repolarization abnormalities.
"may" - Google News
November 09, 2021 at 04:00AM
https://ift.tt/3wsnmDc
Some cancer immunotherapies may increase the risk of myocarditis - Cardiovascular Business
"may" - Google News
https://ift.tt/3foH8qu
https://ift.tt/2zNW3tO
Bagikan Berita Ini
0 Response to "Some cancer immunotherapies may increase the risk of myocarditis - Cardiovascular Business"
Post a Comment